Compare AstraZeneca plc (AZN) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Marsh & McLennan Companies, Inc. — how do they compare? AstraZeneca plc trades at $158.41 (market cap $248.14B), while Marsh & McLennan Companies, Inc. trades at $191.32 (market cap $91.27B). The key difference: AstraZeneca plc is far larger — about 2.7× Marsh & McLennan Companies, Inc.'s market cap, and Marsh & McLennan Companies, Inc. pays the higher dividend (2.07%). Which is the better fit depends on your goals.
| AZN | MRSH | |
|---|---|---|
Market Cap | $248.14B | $91.27B |
Sector | Health | Financials |
52-Week High | $209.48 | $211.21 |
52-Week Low | $147.06 | $157.32 |
Enterprise Value | $275.41B | $111.95B |
Dividend Yield | 2.01% | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Marsh & McLennan (MRSH) trades at $188.81, down 1.04% today, but maintains a bullish technical trend with strong fundamentals. The company reported Q2 2026 EPS of $2.96, beating estimates, and has consistently exceeded earnings expectations. Revenue growth remains solid at 6% in Q2 2026, driven by risk and consulting services. Recent acquisitions, like the planned purchase of Accel Holdings, aim to expand its Midwest insurance reach.
The outlook is positive with a consensus price target of $202.89, suggesting 7.5% upside. Risks include margin pressure from rising expenses and soft P&C pricing. Analyst sentiment is mixed with 30.3% buy ratings but 66.7% hold, indicating cautious optimism. Institutional activity shows new positions by Ashton Thomas Securities and Bank of Nova Scotia, supporting long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
